Moderna, Inc. (MRNA)
Moderna Q3 Revenue Beats On Updated COVID-19 Vaccine, Slashes Expenses For 2024
On Thursday, Moderna Inc MRNA stock is trading higher after the company reported better-than-expected third-quarter sales.
Moderna (MRNA) Q3 Earnings and Revenues Surpass Estimates
Moderna (MRNA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $1.89 per share. This compares to loss of $1.39 per share a year ago.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, impact of President-elect Trump's election victory, status of the company's cancer vaccine, and more.
Moderna's stock pops after biotech ekes out profit and revenue beats by a wide margin
Moderna Inc.'s stock jumped 5% early Thursday, after the company's third-quarter earnings showed an unexpected profit and revenue that beat estimates by a wide margin.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected. Moderna said Thursday its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Moderna, Inc. MRNA will release earnings results for its third quarter, before the opening bell on Thursday, Nov. 7.
Moderna CEO Bancel steps down as sales chief, Bloomberg Law reports
Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial officer, Bloomberg Law reported on Tuesday citing one person familiar with the matter.
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?
When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Moderna (MRNA) closed at $55.22, indicating a +0.77% shift from the previous trading day.
Moderna Stock Price Target Slashed. It's About Vaccines.
The drug maker's shares have dropped 46% so far this year and 56% in the past three months.
